ArticleAntioxidants (Basel, Switzerland)2026
Lutein Attenuates Lipid Accumulation in Association with TFEB Nuclear Translocation and Autophagy-Lysosomal Responses in a Cellular Model of Hepatic Steatosis.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lutein is a dietary xanthophyll carotenoid valued for its antioxidant properties that has been shown to benefit liver health and reduce hepatic lipid accumulation; however, this lipid-lowering effect cannot be fully attributed to its antioxidant activity, and the underlying mechanism remains poorly understood. Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive hepatic lipid accumulation, oxidative stress, and limited therapeutic options. Transcription factor EB (TFEB) coordinates the autophagy-lysosomal pathways involved in cellular lipid clearance, including lipophagy and lysosomal exocytosis, and is sensitive to the cellular redox state; however, whether the antioxidant lutein modulates TFEB-regulated lipid homeostasis remains unclear. HepG2 cells were exposed to free fatty acids (FFAs) to induce intracellular lipid accumulation and co-treated with lutein. TFEB localization and the expression of TFEB-related genes were assessed by immunofluorescence and qPCR, respectively. Immunofluorescence was also used to evaluate lipid droplet accumulation, LC3 content, and LAMP1 localization. Lipid droplet ultrastructure was analyzed by transmission electron microscopy, and extracellular triglyceride levels were measured as a functional readout of lipid extrusion. Lutein attenuated lipid droplet accumulation in FFA-treated cells, increased nuclear TFEB immunoreactivity, upregulated LC3 mRNA expression, and enhanced LC3 colocalization with lipid droplets. Chloroquine abolished the lipid-lowering effect of lutein, supporting an autophagy-dependent mechanism. In addition, lutein increased the abundance of LAMP1-positive compartments, while ultrastructural analysis and elevated extracellular triglyceride levels suggested enhanced lipid extrusion. These findings position the antioxidant lutein as a candidate natural compound whose lipid-lowering action is associated with TFEB nuclear translocation/activation and with the autophagy-lysosomal pathway, warranting further investigation in MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.